Kerry Schaffer

631 total citations
19 papers, 269 citations indexed

About

Kerry Schaffer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kerry Schaffer has authored 19 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Kerry Schaffer's work include Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Renal cell carcinoma treatment (4 papers). Kerry Schaffer is often cited by papers focused on Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Renal cell carcinoma treatment (4 papers). Kerry Schaffer collaborates with scholars based in United States, Austria and Georgia. Kerry Schaffer's co-authors include Chunkit Fung, Paul C. Dinh, Sophie D. Fosså, Lois B. Travis, Shirin Ardeshir‐Rouhani‐Fard, Jacquelyn Powers, Heather H. Cheng, Oliver Sartor, Kah Poh Loh and Richard F. Dunne and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Kerry Schaffer

16 papers receiving 265 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kerry Schaffer United States 9 112 88 84 40 37 19 269
Maria J. Baker United States 10 120 1.1× 58 0.7× 109 1.3× 67 1.7× 96 2.6× 19 476
Tina Rizack United States 9 127 1.1× 33 0.4× 56 0.7× 39 1.0× 42 1.1× 20 336
N.K. Shukla India 10 132 1.2× 116 1.3× 131 1.6× 20 0.5× 43 1.2× 35 329
Xiaoming Cao United States 11 120 1.1× 60 0.7× 67 0.8× 71 1.8× 84 2.3× 27 347
D.Y.S. Kuo United States 10 66 0.6× 43 0.5× 73 0.9× 21 0.5× 34 0.9× 20 321
Kristen Starbuck United States 10 84 0.8× 49 0.6× 105 1.3× 15 0.4× 56 1.5× 29 314
Michael Daugherty United States 12 38 0.3× 167 1.9× 166 2.0× 40 1.0× 81 2.2× 39 364
Aida Moeini United States 14 104 0.9× 59 0.7× 42 0.5× 38 0.9× 45 1.2× 31 519
Byron Sigel United States 8 82 0.7× 56 0.6× 31 0.4× 21 0.5× 38 1.0× 15 265
E. Barrow United Kingdom 8 172 1.5× 70 0.8× 158 1.9× 107 2.7× 36 1.0× 8 489

Countries citing papers authored by Kerry Schaffer

Since Specialization
Citations

This map shows the geographic impact of Kerry Schaffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry Schaffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry Schaffer more than expected).

Fields of papers citing papers by Kerry Schaffer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerry Schaffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry Schaffer. The network helps show where Kerry Schaffer may publish in the future.

Co-authorship network of co-authors of Kerry Schaffer

This figure shows the co-authorship network connecting the top 25 collaborators of Kerry Schaffer. A scholar is included among the top collaborators of Kerry Schaffer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry Schaffer. Kerry Schaffer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Moses, Kelvin A., Jennifer Gordetsky, Sam S. Chang, et al.. (2025). Extensive necrosis as a prognostic indicator in metastatic RCC patients undergoing deferred cytoreductive nephrectomy after immunologic checkpoint inhibitor treatment.. Journal of Clinical Oncology. 43(5_suppl). 468–468.
2.
Gettel, Cameron J., Craig Rothenberg, Kerry Schaffer, et al.. (2025). Emergency department visits among rural and urban older adults: disparities in ambulatory and emergency care sensitive conditions. BMC Health Services Research. 25(1). 975–975. 1 indexed citations
3.
Beckermann, Kathryn E., Jennifer Gordetsky, Sam S. Chang, et al.. (2025). Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors. The Oncologist. 30(4).
4.
Fahey, Catherine C., Caroline A. Nebhan, Sally J. York, et al.. (2023). Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin. International Journal of Molecular Sciences. 24(22). 16109–16109. 11 indexed citations
5.
Schaffer, Kerry, Mingjian Shi, John P. Shelley, et al.. (2023). A Polygenic Risk Score for Prostate Cancer Risk Prediction. JAMA Internal Medicine. 183(4). 386–386. 8 indexed citations
6.
Dombroski, Jenna A., et al.. (2023). Activation of Dendritic Cells Isolated from the Blood of Patients with Prostate Cancer by Ex Vivo Fluid Shear Stress Stimulation. Current Protocols. 3(12). e933–e933. 4 indexed citations
7.
Shi, Mingjian, John P. Shelley, Kerry Schaffer, et al.. (2023). Clinical consequences of a genetic predisposition toward higher benign prostate-specific antigen levels. EBioMedicine. 97. 104838–104838.
8.
Hall, Mary E., Zachary Klaassen, Diana Magee, et al.. (2023). Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs. Clinical Genitourinary Cancer. 21(5). e370–e377. 1 indexed citations
9.
10.
11.
Chen, Yu‐Wei, Matthew D. Tucker, Landon C. Brown, et al.. (2022). Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 40(16_suppl). 4527–4527. 1 indexed citations
12.
Tucker, Matthew D., Landon C. Brown, Yu‐Wei Chen, et al.. (2021). Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker Research. 9(1). 80–80. 28 indexed citations
13.
Wong, Hong Yuen, Kerry Schaffer, Tamara L. Lotan, et al.. (2021). A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer. The Journal of Pathology Clinical Research. 7(3). 271–286. 11 indexed citations
14.
15.
Schaffer, Kerry, Kah Poh Loh, Ian R. Kleckner, et al.. (2019). Systematic Review of Randomized Controlled Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer. Journal of the National Comprehensive Cancer Network. 17(1). 57–63. 53 indexed citations
16.
Schaffer, Kerry, Kah Poh Loh, Ian R. Kleckner, et al.. (2018). A systematic review of randomized controlled trials (RCTs) of exercise interventions using digital activity trackers (E-DAT) in cancer patients.. Journal of Clinical Oncology. 36(7_suppl). 108–108. 3 indexed citations
17.
Graupp, Matthias, et al.. (2018). C‐reactive protein is an independent prognostic marker in patients with tongue carcinoma ‐ A retrospective study. Clinical Otolaryngology. 43(4). 1050–1056. 11 indexed citations
18.
Cheng, Heather H., Jacquelyn Powers, Kerry Schaffer, & Oliver Sartor. (2018). Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer. American Society of Clinical Oncology Educational Book. 38(38). 372–381. 21 indexed citations
19.
Fung, Chunkit, Paul C. Dinh, Shirin Ardeshir‐Rouhani‐Fard, et al.. (2018). Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. Advances in Urology. 2018. 1–20. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria J. Baker Breakdown of academic impact, for papers by Tina Rizack Breakdown of academic impact, for papers by N.K. Shukla Breakdown of academic impact, for papers by Xiaoming Cao Breakdown of academic impact, for papers by D.Y.S. Kuo Breakdown of academic impact, for papers by Kristen Starbuck Breakdown of academic impact, for papers by Michael Daugherty Breakdown of academic impact, for papers by Aida Moeini Breakdown of academic impact, for papers by Byron Sigel Breakdown of academic impact, for papers by E. Barrow
Rankless by CCL
2026